BioDiem advances development of fungal disease treatment


BioDiem’s (ASX: BDM) novel antimicrobial, BDM-I, has moved into the preclinical animal studies phase to assess its potential as a treatment for the fungal disease, pneumocystosis.

BDM-I is a synthetic compound targeting the treatment of serious human infections, while pneumocystis is a difficult-to-treat fungus that can cause serious pneumonia in the aged and infants, as well as those who are ill or have a weakened immune system.

Two new studies will be conducted under the U.S. National Institute of Allergy and Infectious Diseases’ (NIAID) preclinical services program, which earlier assessed BDM-I’s effectiveness in vitro against 70 different strains of opportunistic or hospital-acquired fungi with significant medical need for better treatments.

This earlier data showed that BDM-I had significant activity against infection caused by the organism, pneumocystis spp.

The new study will involve NIAID’s Animal Models of Infectious Disease Program, where a NIAID-funded contractor will conduct studies in a mouse model of pneumocystis infection to assess both optimal dose and overall effectiveness of BDM-I as a novel treatment.

Pneumocystis prevalence

Pneumocystis is a yeast-like fungus that many healthy people carry without symptoms.

However, in patients with a suppressed or compromised immune system, such as cancer patients and particularly HIV patients, it is very problematic causing pneumonia which is a major cause of death in patients who do not have preventative treatment.

In the U.S., the incidence of pneumocystis pneumonia is estimated to be 9% among hospitalised HIV/AIDS patients and 1% among solid organ transplant recipients.

In immuno-compromised patients, the mortality rate ranges from 5% to 40% in those who receive treatment. The mortality rate approaches 100% without therapy.


BDM-I is in the preclinical stage with out-licensing the planned outcome of the antimicrobial’s development.

Patent applications for BDM-I have been granted in China, Russia, Singapore and Australia, as well as in three of the world’s largest patent jurisdictions – Europe, Japan and the U.S.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: BioDiem

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Guild Esports are 'betting big' after signing top five team in Europe just...

Guild Esports's (LON:GILD) Carleton Curtis talks to Proactive London's Katie Pilbeam about landing a top Swedish team as a new signing - which he says means 'the sky is the limit'. This top-tier squad competing in Valorant, which is a 'stunning game', a 5v5 competitive shooter game launched...

9 hours, 34 minutes ago

2 min read